This site is intended for health professionals only

Published on 1 July 2007

Share this story:
Twitter
LinkedIn
RELATED ARTICLES
Happy Anniversary EAHP!
New class of anti-cancer drug
CHMP passes ruxolitinib for splenomegaly
Health research spending tops US$160 billion
NICE rejects Zytiga as prostate cancer treatment before chemotherapy

Monitoring of hazardous drugs

teaser

Jean-Fran



Most read

1
User-friendly osteoporosis therapy launched
2
Helapet introduce new, improved 20mm Vented Vial Adapter
3
Janssen-Cilag’s Stelara approved by NICE
4
Merck agrees huge Vioxx settlement
5
Issues affecting access to orphan drugs in Europe



Latest Issue

Read the latest issue >
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
Share this story:
Twitter
LinkedIn
RELATED ARTICLES
Vitamin D winter study “a success”
FDA warning over HIV drugs use
Study sees scientists track MRSA
Combination beats COX-2 inhibitor alone
MHRA imposes restricted indications on Esmya for uterine fibroids